We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Growth Factor Relieves Symptoms of Parkinson's Disease

By Biotechdaily staff writers
Posted on 08 Apr 2003
In a phase 1 clinical trial, a growth factor administered by catheter to the brains of patients with advanced Parkinson's disease produced an improvement in their motor skills as well as the ability to store dopamine, which helps the brain control muscles. More...
The results were reported in the March 31, 2003, issue of Nature Medicine.

The growth factor used is a protein known as glial cell-line-derived neurotrophic factor, or GDNF. Every day for 18 months, pumps pushed up to 40 micrograms of the protein into the putamen of the brain. There, it was absorbed by cells near the tip of the catheter and, the researchers suspect, drawn deeper into the brain where the dopamine-producing cells reside. After one year, the patients exhibited no serious side effects. The treatment also lessened the tremors caused by L-dopa. Tests measuring motor skills showed a 39% improvement, while tests measuring daily living activities showed a 61% improvement.

"What we're seeing is that GDNF either upregulated dopamine metabolism, or it has inspired sprouting (of cells),” said co-author Clive Svendsen, of the University of Wisconsin-Madison (USA). "Either way, you've got more dopamine, which is good news.” The study was carried out at the Frenchay Hospital, Institute of Neurosciences, in Bristol (UK), coordinated by neurosurgeon Steven S. Gill and neurologist Peter Heywood.




Related Links:
Frenchay Hospital

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Automatic Hematology Analyzer
CF9600
New
Fully Automated Urinalysis System
DxU 1800 Fully Automated Urinalysis System
Immunofluorescence Analyzer
IFA System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Alzheimer’s pathology can start 15 to 20 years before symptoms, and validated tools that reach patients earlier help pave the way for earlier detection. (Image Credit: Adobe Stock)

Alzheimer’s Blood Test Becomes First FDA-Cleared Option for Adults as Young as 40

C2N Diagnostics’ PrecivityAD2 blood test was cleared by the U.S. Food and Drug Administration (FDA) on August 20, 2026, for adults as young as 40 who are experiencing signs of cognitive impairment, according... Read more

Pathology

view channel
Image: Adrenal gland tumor stained with hematoxylin and eosin (top) and CYP11B2 (bottom) (Photo courtesy of Christofer Juhlin)

Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism

Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.